Sutro Biopharma (STRO) Competitors $0.90 -0.01 (-0.91%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.00 (+0.29%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. AVIR, NGNE, LFCR, ACB, CTNM, VOR, DBVT, MREO, JBIO, and LXEOShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Atea Pharmaceuticals (AVIR), Neurogene (NGNE), Lifecore Biomedical (LFCR), Aurora Cannabis (ACB), Contineum Therapeutics (CTNM), Vor Biopharma (VOR), DBV Technologies (DBVT), Mereo BioPharma Group (MREO), Jade Biosciences (JBIO), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Its Competitors Atea Pharmaceuticals Neurogene Lifecore Biomedical Aurora Cannabis Contineum Therapeutics Vor Biopharma DBV Technologies Mereo BioPharma Group Jade Biosciences Lexeo Therapeutics Sutro Biopharma (NASDAQ:STRO) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Which has more volatility and risk, STRO or AVIR? Sutro Biopharma has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Is STRO or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -201.32%. Atea Pharmaceuticals' return on equity of -32.55% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Sutro Biopharma-201.32% -852.70% -58.67% Atea Pharmaceuticals N/A -32.55%-30.47% Which has better earnings and valuation, STRO or AVIR? Atea Pharmaceuticals has lower revenue, but higher earnings than Sutro Biopharma. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSutro Biopharma$62.04M1.22-$227.46M-$2.53-0.35Atea PharmaceuticalsN/AN/A-$168.38M-$1.61-2.16 Do institutionals and insiders hold more shares of STRO or AVIR? 97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer STRO or AVIR? Sutro Biopharma currently has a consensus price target of $4.47, suggesting a potential upside of 398.85%. Atea Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 72.91%. Given Sutro Biopharma's higher possible upside, research analysts clearly believe Sutro Biopharma is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer STRO or AVIR? In the previous week, Sutro Biopharma had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Sutro Biopharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.87 beat Sutro Biopharma's score of 0.70 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Sutro Biopharma Positive Atea Pharmaceuticals Very Positive SummaryAtea Pharmaceuticals beats Sutro Biopharma on 8 of the 15 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.60M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.3521.0831.2626.59Price / Sales1.22400.78464.64173.43Price / CashN/A44.6737.7359.36Price / Book-2.368.0910.046.68Net Income-$227.46M-$54.08M$3.27B$265.59M7 Day Performance5.64%2.25%3.17%3.42%1 Month Performance4.85%3.41%4.34%1.09%1 Year Performance-80.95%18.61%44.12%23.84% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma4.2259 of 5 stars$0.90-0.9%$4.47+398.8%-81.1%$76.60M$62.04M-0.35240AVIRAtea Pharmaceuticals2.4611 of 5 stars$3.66flat$6.00+63.9%-6.2%$290.45MN/A0.0070Positive NewsNGNENeurogene2.3705 of 5 stars$19.98-0.1%$46.17+131.1%-45.2%$285.30M$930K0.0090News CoveragePositive NewsLFCRLifecore Biomedical0.8718 of 5 stars$7.59-0.1%$8.00+5.4%+58.9%$284.30M$128.87M-5.79690Positive NewsACBAurora Cannabis0.9467 of 5 stars$5.23+4.8%N/A-13.6%$281.70M$246.72M-27.531,130Positive NewsCTNMContineum Therapeutics3.3128 of 5 stars$10.39+4.5%$22.75+119.0%-49.6%$278.74M$50M0.0031Positive NewsVORVor Biopharma0.3004 of 5 stars$2.06-5.1%N/AN/A$274.90MN/A0.00140News CoveragePositive NewsGap UpDBVTDBV Technologies3.3996 of 5 stars$9.79-2.1%$14.75+50.7%+111.9%$273.90M$4.15M-2.0580MREOMereo BioPharma Group1.8886 of 5 stars$1.74+2.4%$7.40+325.3%-63.3%$270.30M$10M0.0040News CoverageAnalyst ForecastJBIOJade Biosciences2.1653 of 5 stars$7.90-4.0%$16.00+102.5%N/A$268.52MN/A0.0020LXEOLexeo Therapeutics2.5534 of 5 stars$4.66-4.9%$15.33+229.0%-56.1%$264.61M$650K0.0058News Coverage Related Companies and Tools Related Companies Atea Pharmaceuticals Alternatives Neurogene Alternatives Lifecore Biomedical Alternatives Aurora Cannabis Alternatives Contineum Therapeutics Alternatives Vor Biopharma Alternatives DBV Technologies Alternatives Mereo BioPharma Group Alternatives Jade Biosciences Alternatives Lexeo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access